ABLIM3 dsRNA Agents for PTSD and Age-Related Memory Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for post-traumatic stress disorder (PTSD) and age-related memory loss are limited in efficacy.
Innovation Solution
Development of RNAi compositions that target and inhibit the expression of the ABLIM3 gene, using double-stranded ribonucleic acid (dsRNA) agents with specific nucleotide sequences to degrade ABLIM3 mRNA, achieving inhibition levels of at least 30% to 99%, and optionally conjugated with lipophilic moieties for improved efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for PTSD and age-related memory loss are used, then treatment availability is maintained, but treatment efficacy is limited
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (ABLIM3 gene expression) that contributes to PTSD and memory loss pathophysiology. By designing dsRNA agents that specifically bind to and degrade ABLIM3 mRNA, the invention isolates and addresses the harmful molecular component without affecting other therapeutic pathways, thereby improving treatment efficacy while maintaining safety
Solution Approach 2:
The invention changes the molecular parameter of ABLIM3 protein levels in the brain by introducing dsRNA agents that reduce mRNA expression. This parameter change (decreasing ABLIM3 expression by 30-99%) directly addresses the pathophysiological mechanism underlying the diseases, transforming the treatment approach from symptomatic management to mechanism-based therapy
2Reliability
If dsRNA agents are used to inhibit ABLIM3 expression, then treatment potency is improved, but molecular stability challenges arise
Solution Approach 1:
The patent employs chemically modified nucleotides and conjugation technologies to create composite RNA structures. These modifications (such as 2'-O-methyl, phosphorothioate backbones, and lipid conjugates like GalNAc) enhance the molecular stability of dsRNA agents against nucleases and improve pharmacokinetic properties, thereby maintaining high treatment potency while overcoming inherent RNA instability
Solution Approach 2:
The invention introduces delivery vehicles and conjugating moieties as intermediaries between the dsRNA agent and its target. These intermediaries (including lipid conjugates, protein carriers, and nanoparticle systems) protect the RNA from degradation in circulation, facilitate cellular uptake, and enable the dsRNA to reach its target in the brain without being degraded, thus maintaining both stability and potency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dsRNA agents effectively inhibit ABLIM3 expression, potentially reducing PTSD symptoms and age-related memory loss by decreasing ABLIM3 protein levels, offering therapeutic benefits with improved stability, potency, and safety.
Implementation Method 1
RNAi compositions, which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of an ABLIM3 gene
Implementation Method 2
the antisense strand comprises a region of complementarity to an mRNA encoding ABLIM3
Data Source
AI summary
The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a Actin binding LIM protein 3 (ABLIM3) gene, as well as methods of inhibiting expression of an ABLIM3 gene and methods of treating subjects having an ABLIM3-associated disease or disorder, e.g., PTSD or age-related memory loss, using such dsRNAi agents and compositions.